Clinical Trials Logo

Coronavirus 2019 clinical trials

View clinical trials related to Coronavirus 2019.

Filter by:
  • None
  • Page 1

NCT ID: NCT05492552 Completed - Coronavirus 2019 Clinical Trials

Cardiovascular Function and Physical Activity in COVID-19

CV-COVID
Start date: April 7, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to a) assess how coronavirus 2019 (COVID-19) affects cardiac function in middle age and older adults and b) assess if a physical activity intervention (increased daily step count by 2,000) can affect cardiac function in a population with a history of COVID-19.

NCT ID: NCT04843917 Completed - Vaccine Clinical Trials

Immunity Against COVID-19 Vaccine in Healthcare Workers in Argentine

Start date: April 9, 2021
Phase:
Study type: Observational

Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic. Objectives: To determine the variation in the levels of Immunoglobulin G (IgG) antibodies in health workers who received a COVID-19 vaccine.

NCT ID: NCT04371432 Suspended - COVID-19 Clinical Trials

Genetics of COVID-19 Susceptibility and Manifestations

Start date: May 5, 2020
Phase:
Study type: Observational

Background: Coronavirus 2019 (COVID-19, or SARS-CoV-2) is a serious public health problem, and genetics may play a role in how serious the illness becomes in certain people. Genes are the instructions that our body uses to grow and develop. Variations in our genes can cause medical conditions and may be the reason why some people get sicker than others. Objective: This study aims to learn more about the genetic contributions to the severity of COVID-19. We hope to use this information to develop therapies that reduce the severity of COVID-19 symptoms in some people. Eligibility: Anyone located in the United States who has tested positive for SARS-CoV-2 infection may be eligible to join (including NIH staff). Design: Participants will complete a questionnaire about their health history and COVID-19 symptoms. Participants will give a blood or saliva sample. It will be about 2 tablespoons of blood, or we will send a saliva collection kit. Researchers will use this blood or saliva sample to study the participant s DNA. The data about participants genes will be stored in a large database. The database will be shared with other qualified researchers who are trying to learn about COVID-19. Participants names and other personal details will not be shared. Instead, the data will be labeled with a code. Participants may be contacted by study team members for up to a year after they join the study.